World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
47593
World Ranking
13393
National Ranking
397

Overview

Yuichiro Ohe is affiliated with the National Cancer Centre in Japan and has contributed extensively to research in the field of medicine, particularly focusing on pulmonary and respiratory medicine, oncology, and molecular biology. Their work spans multiple subfields including cancer research and surgery.

Their research covers a range of topics in oncology and respiratory medicine, emphasizing lung cancer treatments and mutations, cancer immunotherapy and biomarkers, and lung cancer diagnosis and treatment. Additional areas of focus include colorectal cancer treatments and studies, cancer genomics and diagnostics, and interstitial lung diseases and idiopathic pulmonary fibrosis.

Yuichiro Ohe has authored and co-authored papers in prominent scientific journals and medical periodicals. Some of the recent significant publications include:

  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer, 2020, Annals of Oncology
  • Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial, 2022, The Lancet Oncology
  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial, 2021, Journal of Thoracic Oncology
  • The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning, 2020, Biomolecules

Collaborations have been an integral part of their research practice, with frequent co-authors including Hidehito Horinouchi, Tatsuya Yoshida, Noboru Yamamoto, Yasushi Goto, and Yusuke Okuma.

Yuichiro Ohe's publications frequently appear in several key academic venues, reflecting their active presence in the oncology and respiratory medicine research communities. These venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Lung Cancer
  • Japanese Journal of Clinical Oncology
  • Journal of Thoracic Oncology

Overall, the scientist's contributions are situated mainly within the broad discipline of medicine, with a focus on lung cancer treatments and related biomedical research. Their work intersects clinical trials, therapeutic approaches, and molecular studies aimed at understanding and addressing cancer and respiratory diseases.

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

    Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  • Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

    Toshimi Takano;Yuichiro Ohe;Hiromi Sakamoto;Koji Tsuta

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

    Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

    Suresh S. Ramalingam;James C.-H. Yang;Chee Khoon Lee;Takayasu Kurata

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

    S.S. Ramalingam;Y. Cheng;C. Zhou;Y. Ohe

  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

    G.R. Oxnard;J.C.-H. Yang;H. Yu;S.-W. Kim

  • Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

    Kiyotaka Yoh;Takashi Seto;Miyako Satouchi;Makoto Nishio

  • Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

    Seiji Yano;Tadaaki Yamada;Shinji Takeuchi;Keisei Tachibana

  • Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

    Koichi Goto;Yukito Ichinose;Yuichiro Ohe;Nobuyuki Yamamoto

  • EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

    Toshimi Takano;Tomoya Fukui;Yuichiro Ohe;Koji Tsuta

  • Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

    Shinji Atagi;Masaaki Kawahara;Akira Yokoyama;Hiroaki Okamoto

  • Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

    Toshimi Takano;Yuichiro Ohe;Masahiko Kusumoto;Ukihide Tateishi

  • Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

    Morihito Okada;Takashi Kijima;Keisuke Aoe;Terufumi Kato

  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Luis G. Paz-Ares;Suresh S. Ramalingam;Tudor-Eliade Ciuleanu;Jong-Seok Lee

Frequent Co-Authors

Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Hiroaki Okamoto
Hiroaki Okamoto Jichi Medical University
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Kazuto Nishio
Kazuto Nishio Kindai University
Kanji Nagai
Kanji Nagai Kitasato University
Takashi Kohno
Takashi Kohno National Cancer Centre
Koji Tsuta
Koji Tsuta Kansai Medical University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending in-person classes. There are several related online degree options for those interested in growing their healthcare expertise from home. Many students begin by considering programs like the cheapest bsn programs online, which help prepare future nurses through flexible and affordable study.

If you’re aiming for an advanced nursing career, check out the cheapest fnp programs online and the cheapest dnp programs. These programs offer an accessible pathway to becoming a nurse practitioner or earning a doctoral degree in nursing—all via online learning.

For those interested in working behind the scenes in healthcare, getting certified in medical billing and coding is a practical option. Many wonder about medical coding certification cost and how to choose a program that suits both their budget and timeline.

Online degrees and certifications make it easier than ever to start or advance a career in medicine, while balancing other commitments.

Best Scientists Citing Yuichiro Ohe

Trending Scientists